Contacts: Anthony G. Viscogliosi, Viscogliosi Bros, LLC (212) 583-9700
Chris Storer, Creative Partners (203) 952-6403
BIODEGRABLE CMC SPACERS FOR BASAL THUMB OA DRIVE GROWTH AT SMALL BONE
Surgeons in U.S. and Europe treating more basal
thumb OA cases using Artelon® technology
CHICAGO, IL – March 23, 2006 -
Small Bone Innovations, Inc. (SBI) reported that annual sales in the
U.S. and Europe of its biodegradable Artelon® Spacer CMC-I exceeded
500 units used in treating osteoarthritis (OA) at the base of the thumb.
The condition particularly affects as many as one-in-four post-menopausal
mothers, according to the company.
In its first full year of operation, since its formal introduction at
the 2005 American Academy of Orthopaedic Surgeons (AAOS) annual convention,
SBI has been marketing 42 products used to treat arthritis or trauma
in small bones and joints. Of these, the company said the CMC-I Spacer
is a big seller.
“In one short year, SBI has quickly become identified as the single
source provider of products and services to treat bones and joints from
the finger tips to the shoulder, and from the toes to below the knee.
The Spacer has been our only biologics offering but it has taken off
like a rocket,” Anthony G. Viscogliosi, SBI’s Chairman and
The Spacer technology was developed by Artimplant AB of Sweden (STO:
ARTI-B) and sold worldwide by SBI under an exclusive marketing license.
SBI has similar licenses to develop and sell Artelon® fiber-based
products for use in the hand, wrist, fingers and feet.
“The success of the Artelon® Spacer, according to many of
the 100-plus surgeons using the technology, is its ability to relieve
pain and restore function through improving pinch strength without needing
to harvest tissue from the patient’s body – unlike other
basal thumb procedures,” Viscogliosi said. “It is also a
relatively simple procedure to teach and perform – requiring no
special instrumentation or unfamiliar techniques,” he added.
In addition to its U.S. and European markets, Artimplant has recently
received government approvals that will enable SBI to market the Artelon®
Spacer in Canada and Australia. Also, earlier this month, Artimplant
received a European CE mark that will facilitate SBI’s marketing
of the Artelon® DRU Spacer intended for treatment of OA in the distal
radio-ulnar (DRU) joint of the wrist.
Michael Simpson, SBI’s President and COO, said: “To complement
the Artelon® Spacer, we are adding several other Artelon® designs
for repairing or replacing the CMC joint – all under our original
license – to complete a portfolio of biodegradable implants for
Among those surgeons currently implanting the Spacer, Alejandro Badia,
MD, a leading hand surgeon based in Miami, FL, said: “The use
of tissue-sparing technology holds immense promise. Procedures capable
of restoring function are a compelling alternative to drug therapy or
more aggressive surgical procedures.”
SBI said it plans to initiate a new series of clinical trials in the
U.S. to explore the full potential of the Artelon® technology within
the bounds of its existing licensing agreement with Artimplant AB.
As well as post-menopausal women, SBI estimates that 90 percent of women
in the 75-79 age bracket have symptomatic OA in the hands – among
the 21 million Americans who suffer from the disease in one form or
another. According to the company, only heart disease causes more chronic
disability than does OA. SBI also noted that 25 percent of athletic
injuries occur in the hand and wrist.
Small Bone Innovations, LLC (SBI) was founded in 2004 by Viscogliosi
Bros. LLC., (VB), the New York-based merchant banking firm that specializes
in the musculoskeletal /orthopedic sector. VB created SBI as the first
company to focus purely on small bone & joint science. By integrating
established companies and professionals in the field, SBI today offers
a broad, clinically proven portfolio of products and technologies to
treat trauma and diseases in small bones & joints.
VB’s acquisitions and technology licenses include: Avanta
Orthopaedics (hand/wrist/elbow arthroplasty and trauma products
– USA); Envision (implant manufacturing –
USA); Actipore™ (porous metal technology –
Canada); Artelon® (biologically active & biodegradable
technology – Sweden); Xtremi-T (resorbable trauma
technology – USA); Fixano, S.A.S. (orthopedics,
trauma and spine products - France).
Small Bone Innovations, Inc. (SBI)completed a Series B financing, raising
a record total of $42.2 million, in January, 2006 Based on data provided
by Venture Source, this was the largest venture capital investment ever
recorded in the field of orthopedic devices.
For more information on SBI visit: www.totalsmallbone.com
About Artimplant AB
Artimplant is a public company based in Västra Frölunda, Sweden
and is listed on the Stockholm Exchange, O-list. Artelon® is a degradable
polyurethane-urea patented biomaterial that acts as a temporary support
for healing tissue. For additional information, please contact: Tord
Lendau, CEO, phone +46 (0)31 746 56 00, +46 (0)708 369 403, email: firstname.lastname@example.org
or visit: www.artimplant.com
> Back to Press Releases